The role of secukinumab in the treatment of ankylosing spondylitis

Rashmi Shah, Lisa Perry, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.

Original languageEnglish (US)
Pages (from-to)1241-1247
Number of pages7
JournalImmunotherapy
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Sacroiliac Joint
Ankylosing Spondylitis
Signs and Symptoms
Interleukin-17
Disease Progression
Spine
Anti-Inflammatory Agents
Joints
Monoclonal Antibodies
Magnetic Resonance Imaging
Therapeutics
Pharmaceutical Preparations
secukinumab
Patient Reported Outcome Measures

Keywords

  • ankylosing spondylitis
  • axial spondyloarthritis
  • interleukin-17
  • interleukin-17 inhibitors
  • secukinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

The role of secukinumab in the treatment of ankylosing spondylitis. / Shah, Rashmi; Perry, Lisa; Deodhar, Atulya (Atul).

In: Immunotherapy, Vol. 7, No. 12, 01.12.2015, p. 1241-1247.

Research output: Contribution to journalArticle

Shah, Rashmi ; Perry, Lisa ; Deodhar, Atulya (Atul). / The role of secukinumab in the treatment of ankylosing spondylitis. In: Immunotherapy. 2015 ; Vol. 7, No. 12. pp. 1241-1247.
@article{0015837907a64de5a2d1e0d2e18955b7,
title = "The role of secukinumab in the treatment of ankylosing spondylitis",
abstract = "Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.",
keywords = "ankylosing spondylitis, axial spondyloarthritis, interleukin-17, interleukin-17 inhibitors, secukinumab",
author = "Rashmi Shah and Lisa Perry and Deodhar, {Atulya (Atul)}",
year = "2015",
month = "12",
day = "1",
doi = "10.2217/imt.15.93",
language = "English (US)",
volume = "7",
pages = "1241--1247",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - The role of secukinumab in the treatment of ankylosing spondylitis

AU - Shah, Rashmi

AU - Perry, Lisa

AU - Deodhar, Atulya (Atul)

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.

AB - Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.

KW - ankylosing spondylitis

KW - axial spondyloarthritis

KW - interleukin-17

KW - interleukin-17 inhibitors

KW - secukinumab

UR - http://www.scopus.com/inward/record.url?scp=84948138923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948138923&partnerID=8YFLogxK

U2 - 10.2217/imt.15.93

DO - 10.2217/imt.15.93

M3 - Article

VL - 7

SP - 1241

EP - 1247

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 12

ER -